Orphazyme's board steps down – new major shareholders take over
Individuals linked to the three new leading stakeholders that in short time have acquired a combined 15-30% of Orphazyme are now also taking control of the three seats on the biotech firm’s board.
by cristopher due karlsson, translated by kristoffer grønbæk
Shortly after the three companies MH Investment, Scandinavian Investment Group and Nordic Compound Invest have stepped into Orphazyme’s circle of owners, the biotech company makes alterations to its board of directors.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme nears settlement in US class action lawsuit
For subscribers
